Seer (SEER) Non-Current Deffered Revenue (2020 - 2021)

Seer (SEER) recorded quarterly Non-Current Deffered Revenue of $2.7 million in Q3 2021, up 19.53% quarter-over-quarter from $2.2 million in Q2 2021.

Seer (SEER) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Seer's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $2.7 million for Q3 2021.

In Q3 2021, Non-Current Deffered Revenue changed N/A year-over-year to $2.7 million; the TTM figure through Sep 2021 stood at $2.7 million (changed N/A YoY), while the FY2020 annual figure was $1.9 million, changed N/A from the prior year.
Non-Current Deffered Revenue was $2.7 million for Q3 2021 at Seer, up from $2.2 million in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $2.7 million in Q3 2021 to a low of $1.9 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	-
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	Seer	95.75 Mn	95.75 Mn	982,000.00	-

Download Data